Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INTRA-CELLULAR THERAPIES, INC.

(ITCI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

FDA approves Intra-Cellullar's schizophrenia drug, shares soar 85%

12/23/2019 | 08:48am EDT
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland

Intra-Cellular Therapies Inc said on Monday its lead drug to treat schizophrenia in adults has received approval from the U.S. Food and Drug Administration, sending its shares soaring 85%.

The company said it will price the drug, Caplyta, closer to its launch.

Caplyta, which has been approved as a once-daily dose of 42 mg, has shown to regulate three neurotransmitter systems — serotonin, dopamine and glutamate — linked to severe mental illnesses.

Intra-Cellular plans to launch the drug later in the first quarter of 2020 and is in talks with health insurers on the its potential coverage. The company will market Caplyta on its own worldwide, it said.

The approval comes with FDA's harshest warning that the drug is not for the treatment of patients with dementia-related psychosis.

Schizophrenia is a chronic mental disorder that causes distortion in thoughts, hallucinations and feelings of fright and paranoia, affecting about 2.4 million adults in the United States.

An approval will de-risk the market inefficiency driven by investors' concerns regarding the pace at which Caplyta will be adopted post launch as a differentiated neuropsychiatric product in early 2020, Cantor Fitzgerald analyst Charles Duncan said, ahead of the FDA decision.

"We anticipate first couple of quarters to be driven by pharmacy stockpiling with sales revenue reflecting in the third quarter of 2020," added Fitzgerald.

Existing anti-psychotic drugs in the market include Rexulti from Danish drugmaker H. Lundbeck A/S and Japan’s Otsuka Pharmaceutical Co Ltd, Allergan Plc’s Vraylar and Johnson & Johnson's Invega.

In trials, Caplyta did not cause akathisia, a feeling of jitteriness among patients, which is extraordinarily uncomfortable and makes people "jump out of their skin", the company said.

The drug is also being developed by Intra-Cellular for other indications including bipolar depression, depressive disorders and agitation in patients with Alzheimer’s disease.

Shares of the company were trading at $23 before the bell and were set to open at more than one and a half year high.

By Trisha Roy


ę Reuters 2019
Stocks mentioned in the article
ChangeLast1st jan.
ALLERGAN PLC 0.00%End-of-day quote.0.97%
INTRA-CELLULAR THERAPIES, INC. 2.57% 42.75 Delayed Quote.34.43%
NEXT PLC 0.17% 8068 Delayed Quote.13.86%
ONE STOP SYSTEMS, INC. 7.04% 6.39 Delayed Quote.59.75%
OTSUKA CORPORATION -2.95% 5920 End-of-day quote.8.62%
OTSUKA HOLDINGS CO., LTD. 0.49% 4753 End-of-day quote.7.58%
THE LEAD CO., INC. 2.94% 736 End-of-day quote.-12.38%
All news about INTRA-CELLULAR THERAPIES, INC.
06/08INTRA CELLULAR THERAPIESá : CAPLYTA (lumateperone) Schizophrenia Safety and Tole..
AQ
06/07INTRA CELLULAR THERAPIESá : CAPLYTA« (lumateperone) Schizophrenia Safety and Tol..
AQ
06/01INTRA CELLULAR THERAPIESá : Significant Insider Selling in Shares of Intra-Cellu..
MT
05/31INTRA CELLULAR THERAPIESá : Insider Sale at Intra-Cellular Therapies (ITCI) Cont..
MT
05/28INSIDER TRENDS : Insider Prolongs 90-Day Selling Trend at Intra-Cellular Therapi..
MT
05/26INTRA CELLULAR THERAPIESá : Insider Sale at Intra-Cellular Therapies (ITCI) Deem..
MT
05/26Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
GL
05/25INSIDER TRENDS : Selling By Insiders Lingers at Intra-Cellular Therapies
MT
05/12INTRA CELLULAR THERAPIESá : REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PRO..
PU
05/11INTRA CELLULAR THERAPIESá : RBC Boosts Price Target on Intra-Cellular Therapies ..
MT
More news
Financials (USD)
Sales 2021 96,0 M - -
Net income 2021 -260 M - -
Net cash 2021 799 M - -
P/E ratio 2021 -13,5x
Yield 2021 -
Capitalization 3 471 M 3 471 M -
EV / Sales 2021 27,8x
EV / Sales 2022 10,2x
Nbr of Employees 383
Free-Float 95,0%
Chart INTRA-CELLULAR THERAPIES, INC.
Duration : Period :
Intra-Cellular Therapies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTRA-CELLULAR THERAPIES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 51,13 $
Last Close Price 42,75 $
Spread / Highest target 89,5%
Spread / Average Target 19,6%
Spread / Lowest Target -6,43%
EPS Revisions
Managers and Directors
NameTitle
Sharon Mates Chairman, President & Chief Executive Officer
Lawrence J. Hineline Chief Financial Officer, Treasurer & SVP-Finance
Robert E. Davis Chief Scientific Officer & Senior Vice President
Suresh Durgam Chief Medical Officer & Senior Vice President
Karen Patruno Sheehy Chief Compliance Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
INTRA-CELLULAR THERAPIES, INC.34.43%3 471
GILEAD SCIENCES, INC.16.98%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE170.58%57 615
REGENERON PHARMACEUTICALS9.45%54 424
VERTEX PHARMACEUTICALS-17.58%49 966